European pharma industry funds project to promote biologics development

6 March 2017

A new project has been launched to understand the factors associated with the development of advanced therapy medicinal p[roducts (ATMPs) in Europe, with the aim of promoting and accelerating the launch of new products in this area.

The project is being launched by Lygature, a Dutch not-for-profit foundation that seeks to encourage public-private collaboration in order to catalyse new medical solutions.

ATMPs are a particular class of biopharmaceutical product, based on genes, cells or tissue engineering, that are identified by the European Medicines Agency as offering groundbreaking opportunities for the treatment of disease and injury.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK